Search Results - "Grischke, E.M."

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial by Dinkic, C, Eichbaum, M, Schmidt, M, Grischke, E.M, Gebauer, G, Fricke, H.C, Lenz, F, Wallwiener, M, Marme, F, Schneeweiss, A, Sohn, C, Rom, J

“…Highlights • Pazopanib with cyclophosphamide had a MTD of 600 mg per day. • Main side effects were elevation of the liver enzymes, diarrhea, leukopenia. •…”
Get full text

Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results by Wuerstlein, R, Grischke, E.M, Gluz, O, Kates, R, Persoon, M, Thill, M, Hasmueller, S, Knauer, M, Pusch, R, Harbeck, N

Get full text

1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO by Lüftner, D, Grischke, E.M, Fasching, P, Decker, T, Schneeweiss, A, Uleer, C, Foerster, F, Wimberger, P, Kluth-Pepper, B, Schubert, J, Bloch, W, Tesch, H, Schuetz, F, Jackisch, C

Get full text

Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019) by Clover, A.J.P., de Terlizzi, F., Bertino, G., Curatolo, P., Odili, J., Campana, L.G., Kunte, C., Muir, T., Brizio, M., Sersa, G., Pritchard Jones, R., Moir, G., Orlando, A., Banerjee, S.M., Kis, E., McCaul, J.A., Grischke, E.M., Matteucci, P., Mowatt, D., Bechara, F.G., Mascherini, M., Lico, V., Giorgione, R., Seccia, V., Schepler, H., Pecorari, G., MacKenzie Ross, A.D., Bisase, B., Gehl, J.

“…Electrochemotherapy (ECT) is a treatment for both primary and secondary cutaneous tumours. The international Network for sharing practices on ECT group…”
Get full text

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial by Gluz, O., Kuemmel, S., Nitz, U., Braun, M., Lüdtke-Heckenkamp, K., von Schumann, R., Darsow, M., Forstbauer, H., Potenberg, J., Uleer, C., Grischke, E.M., Aktas, B., Schumacher, C., zu Eulenburg, C., Kates, R., Jóźwiak, K., Graeser, M., Wuerstlein, R., Baehner, R., Christgen, M., Kreipe, H.H., Harbeck, N.

“…In high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) early breast cancer (EBC), nanoparticle albumin-bound…”
Get full text

Electrochemotherapy in the treatment of cutaneous malignancy; outcomes and subgroup analysis from the cumulative results from the pan- European InspECT Database for 1478 lesions in 691 patients (2008-2018) by Clover, A.J.P., Bertino, G., Curatolo, P., Odili, J., Campana, L., Kunte, C., Muir, T., Brizio, M., Sersa, G., Liew, S.H., Moir, G., Orlando, A., Banerjee, S.M., Kis, E., McCaul, J.A., Grischke, E.M., Matteucci, P., Gehl, K.J.

Get full text

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study by Mavratzas, A., Baek, S., Gerber, B., Schmidt, M., Moebus, V., Foerster, F., Grischke, E.M., Fasching, P., Strumberg, D., Solomayer, E., Klare, P., Windemuth-Kieselbach, C., Hartmann, S., Schneeweiss, A., Marmé, F.

“…This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor…”
Get full text

P255 - Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results by Wuerstlein, R., Grischke, E.M., Gluz, O., Kates, R., Persoon, M., Thill, M., Hasmueller, S., Knauer, M., Pusch, R., Harbeck, N.

Get full text

158. Pathological Complete Response is not the Best Prognostic Factor in Patients with Breast Cancer Treated by Preoperative Chemotherapy by Honig, A., Solomayer, E.F., Sinn, H.P., Meyberg, G.C., Grischke, E.M., Bastert, G., Wallweiner, D.

Get full text

Adjuvant cisplatin and treosulfan chemotherapy in epithelial ovarian cancer stage I–III after complete surgical resection by Grischke, E.M., Felderbaum, R., Breitbach, G.P., Bastert, G.

Get full text

Low neurotoxicity of chemotherapy with Carboplatin/Docetaxel for reccurent epithelial ovarian cancer by Meyer, A., Huober, J., Goerner, R., Grischke, E.M., Wagner, U., Bastert, G., Wallwiener, D.

Get full text

Surgical procedure can explain varying influence of menstrual cycle on prognosis of premenopausal breast cancer patients by von Minckwitz, G., Kaufmann, M., Dobberstein, S., Grischke, E.M., Diel, I.J.

“…The mechanism of how menstrual cycle influences prognosis of premenopausal breast cancer patients is still unclear. In an analysis of 266 premenopausal…”
Get full text

Treatment of bacterial infections of the female urinary tract by immunization of the patients by Grischke, E M, Rüttgers, H

“…In an open comparative study 400 patients with urinary tract infections were randomly allocated to two treatment groups. In 202 patients an immune stimulation…”
Get more information

Akardius oder "Twin-Reversed-Arterial-Perfusion"-Sequenz by Sergi, C., Grischke, E.M., Schnabel, P.A., Sippel, F., Adam, S., Krempien, B., Otto, H.F.

Get full text

Tumor debulking and IORT for recurrent gynecological carcinomas of the pelvic sidewall by Eble, M J, Wallwiener, D, Junkermann, H, Schmid, H, Solomayer, E F, Grischke, E M, Wannenmacher, M, Bastert, G

Get more information